|
Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study Clinical research trials and Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study. Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study clinical trial. Human subjects often receive the most effective healthcare possible for their Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study  Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
For Condition: Alzheimer Disease
Status: Recruiting
Sponsor(s): Voyager Pharmaceutical Corporation ,
Synopsis: ALADDIN is a research study to investigate the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD) in men 65 years and older with mild to moderate Alzheimer's disease who reside in the community.
Details: ALADDIN is a clinical trial investigating the safety and effectiveness of leuprolide (a hormone drug) to improve the cognitive function and slow the progression of Alzheimer's disease (AD). The study will include treatment of men 65 years and older with mild to moderate Alzheimer's disease who reside in the community. The objective is to evaluate the safety and efficacy of two different doses of leuprolide to improve the cognitive function and slow the progression of AD, as measured by the ADAS-COG and the Clinical Global Impression (CGI). Measures of behavioral disturbances, and quality of life of the caregiver will be made also. The study design is randomized, double blind, placebo-controlled, parallel group design with a 2:1 randomization of drug to placebo. Sample size will include 90 participants from multiple test sites. Following initial screening and baseline visits, the participant and caregiver will visit the site 8 times for a total of 10 visits over 48 months. The drug is administered via injection every 3 months. Safety assessments are completed and psychometric testing is done. Participant's memory, behavior, and global functioning are assessed during the participant and caregiver interviews. Each visit takes approximately 2 hours.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 65 Years/
Genders: Male
Protocol Entry Criteria: Inclusion Criteria: Patients who satisfy all of the inclusion criteria listed below will be eligible for entry into the trial. - Patient and responsible caregiver can give their consent by signing the IRB-approved Informed Consent Form; or, when the patient is judged by the Investigator to be unable to give consent, the legally authorized representative gives consent by signing the consent form and the patient gives assent, in accord with local regulations; - Male; - 65 years of age or older; - Diagnosis of probable AD according to the National Institute of Neurological Disorders-Alzheimer's Disease and Related Disorders Association (NINDS-ADRDA) criteria, and the Investigator ascertains that the condition was present at least 6 months prior to screening; - Taking a drug for the treatment of AD, such as a cholinesterase inhibitor and/or Memantine®, which they began taking at least 90 days prior to baseline and, in the Investigator's opinion, the dosage will likely remain stable throughout the trial; or, they have never taken such a drug or stopped taking it at least 90 days prior to baseline and will likely refrain from taking such treatment throughout the trial; - Taking other drugs or substances that have purported cognition-enhancing properties such as ginkgo biloba or Vitamin E, which they began taking at least 60 days prior to baseline and, in the Investigator's opinion, the dosage will likely remain stable throughout the trial; or, they have never taken such a drug or stopped taking it at least 90 days prior to baseline and will likely refrain from taking such treatment throughout the trial; - Mini Mental State Examination (MMSE) score of 12 to 24 (inclusive) at the screening visit; - Brain imaging study (CT scan, MRI or PET) performed at the time of their initial diagnosis of AD or after that time, and the findings were consistent with a diagnosis of probable AD, or, if a brain imaging study has not been performed, one will be performed during the screening process; - Rosen Modified Hachinski score of 4 or lower at the screening visit, supporting the Investigator's clinical judgment that the patient's dementia is probable AD and not of vascular origin; - Fluent in English or Spanish and completed at least 6 years of education; - Live at home or in a congregate living facility for requirements other than skilled nursing care, and have a caregiver who sees the patient at least three times a week for a total of at least 10 hours and can sign the consent form, provide information pertinent to the patient's cognitive status, accompany the patient on clinic visits, and participate in the evaluations. - Hamilton Depression Scale (17-item version) (HamD) score of 14 or less at the screening visit; - DEXA scan, performed at screening, within normal limits (i.e., a T-score of greater than -2.0); or, if their DEXA measure was abnormally low (i.e., a T-score of -2.0 or lower), in either a lumbar vertebra or hip, to specifically include a T-score for the femoral neck), they were receiving treatment for osteoporosis/osteopenia for at least 3 weeks prior to baseline and that treatment is not expected to change during the course of the trial; or, if their DEXA measure was abnormally low and they are not receiving treatment for osteoporosis/osteopenia, they may proceed to baseline after 3 weeks of treatment for osteoporosis/osteopenia provided that all inclusion/exclusion criteria are met, including assessment of the HamD, concomitant medications, ECG and laboratory tests performed within 45 days of baseline show that they are eligible; - Screening laboratory test values do not indicate significant medical conditions that would interfere with their participation in and completion of the study. Exclusion criteria: Patients with any of the exclusion criteria listed below will be ineligible for entry into the study. - Female; - Younger than 65 years of age; - Significant neurological disease affecting the brain or psychiatric disease other than AD, such as major depression, schizophrenia, epilepsy, Parkinson's disease, or stroke; - Current significant systemic illness or symptoms of organ failure; - Screening ECG shows evidence of a serious and/or unstable condition or a recent (within 6 months) myocardial infarction as determined by the Investigator; - PSA test result exceeds 4.0 ng/mL; - Receiving testosterone; - Taking a drug for the treatment of AD for less than 90 days prior to baseline; or, in the opinion of the Investigator, they are likely to either require a change in dose or discontinuation of the drug; - Never received cholinesterase inhibitor treatment, and the likelihood of their starting such treatment during the study is other than low, or they have taken and discontinued cholinesterase inhibitor treatment in the past and the likelihood of their resuming cholinesterase inhibitor treatment during the study is other than low; - Started or changed within 60 days prior to the screening visit the dosage of any drug (including OTC) that affects cognitive function, such as neuroleptics, antidepressants, anxiolytics, sedatives, hypnotics, anti-convulsants, centrally acting antihypertensive agents such as clonidine and Aldomet; or other medications that have been shown to have possible effects on cognition such as Vitamin E, nonsteroidal anti-inflammatory drugs, and statins, or if, in the Investigator's opinion, the dosage of such medication is likely to be changed during the course of this trial. Any changes in the dosage of any of these drugs during the course of the trial and the reason for the change must be fully recorded in the concomitant medication page of the patient's case report form (CRF). If a drug that affects cognition (e.g., a hypnotic or anxiolytic drug) is given on a PRN basis, such treatment should be interrupted for 12 hours before a visit, if possible; - Taking coumadin or anti-Parkinsonian medications; - Have taken other investigational drugs within 30 days or 5 half-lives prior to randomization, whichever is longer; - Taking other medications known to affect serum gonadotropin (Gn) concentrations, such as gosorelin or danazol; - A screening HamD score of 15 or higher; - Abuse or dependence on alcohol or other substances satisfies criteria for DSM-IV categories 303.9 or 305; - Donated blood within 30 days of baseline or are likely to do so during the course of the trial; - History of cancer, particularly breast cancer or known or suspected prostate cancer, within the last 5 years, except for basal cell or squamous cell cancer of the skin; - Clinically significant bladder outlet obstruction, in the judgment of the Investigator or designated examining physician; - Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia, or are unable to stand or sit upright for at least 30 minutes; - Sleep apnea.
Total Enrollment: 90
Location and Contact Information:
Overall Study Official:
RichardBowen, Principal Investigator, Voyager Pharmaceutical Corporation
Boston University School of Medicine *Not yet recruiting*
Boston, Massachusetts, 02118-2526
United States
Not yet recruiting
Health Quest *Recruiting*
San Diego, California, 92123
United States
Recruiting Niki Sharif 858-571-1188
Baumel-Eisner Neuromedical Institute *Recruiting*
Ft. Lauderdale, Florida, 33321
United States
Recruiting Fanny Levinson 954-720-1899
Middleton VA Wisconsin Alzheimer's Institute *Recruiting*
Madison, Wisconsin, 53705
United States
Recruiting Tracy Ohrt 608-256-1901
Baumel-Eisner Neuromedical Institute *Recruiting*
Miami, Florida, 33154
United States
Recruiting Beth Safirstein 305-865-0063
Meridien Research *Recruiting*
St. Petersburg, Florida, 33710
United States
Recruiting Cathy Collins 727-347-8839
Medical University of South Carolina *Recruiting*
Charleston, South Carolina, 29406
United States
Recruiting Virginia Pooser 843-740-6113
Baumel-Eisner Neuromedical Institute *Recruiting*
Boca Raton, Florida, 33486
United States
Recruiting Mery Lossada 561-368-1123
Innovative Clinical Research Center *Recruiting*
Alexandria, Virginia, 22304
United States
Recruiting Chris Battle 703-212-5907
Additional Information:
Study ID Numbers: IA0051;
Study Start Date: December 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00076440
Other Alzheimer Disease Studies:
1. The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
2. Vitamin E in Aging Persons With Down Syndrome
3. Study of Melatonin: Sleep Problems in Alzheimer's Disease
4. Huperzine A in Alzheimer's Disease
5. Memory Impairment Study (Mild Cognitive Impairment Study)
Related Studies:
Other Alzheimer Disease Clinical Trials
Other Virginia Clinical Trials
Other Alexandria Clinical Trials
Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study
|
|
|
|
|
|
|
|
